Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Liver Metastases: early-phase trial registry
14 of 28 indexed Liver Metastases trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #577 of 28,707 conditions by registered trial count.
28 US clinical trials · 14 currently recruiting · #577 of 28,707 conditions by registered trial count
Liver Metastases: 28 US clinical trials tracked, 14 recruiting.
Liver Metastases is the subject of 28 registered US clinical trials on ClinicalTrials.gov, 14 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 13 in Phase 1-2 (earlier-stage). The most active sponsor is Roger Williams Medical Center, running 2 of these trials.
Enrollment posture brief
Registry condition liver-metastases
OPEN 14 | RECR 50% | LATE 0 | EARLY 13 | RANK #577 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Abdominal Aortic Aneurysms (50% recruiting · 6 trials)
Liver Metastases lists 14 open slots (50% of 28 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Liver Metastases on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Liver Metastases is recruiting above its size-band peers.
14 of 28 indexed trials (50%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Liver Metastases trials is spread across many organizations.
Roger Williams Medical Center accounts for 2 of 28 trials (7.1%). 23 distinct sponsors appear on at least one study for this condition label.
-
Most Liver Metastases trials plan to enrol fewer than 100 people.
Median target enrolment is 32 among the 28 trials that report a genuine target (sentinel values excluded). 22 of those (78.6%) plan for fewer than 100 participants.
-
Liver Metastases research is mostly interventional.
25 interventional and 3 observational studies make up this index (89.3% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
28 total, page 1 of 1
Stereotactic Magnetic Resonance Guided Radiation Therapy
Dana-Farber Cancer Institute
NCT04115254
Tissue Analysis After Tumor Ablation for Liver Metastases Leading to Immediate Retreatment
Memorial Sloan Kettering Cancer Center
NCT04143516
ctDNA-Directed Post-Hepatectomy Chemotherapy for Patients With Resectable Colorectal Liver Metastases
M.D. Anderson Cancer Center
NCT05062317
Histotripsy Plus Chemotherapy vs Chemotherapy Alone for Advanced Colorectal Liver Metastasis
Case Comprehensive Cancer Center
NCT07044362
REGULUS: MRI-guided Adaptive SABR for Liver Cancers
Stanford University
NCT07223307
HepQuant: Study to Assess the Role of Blood-based Biomarkers and Quantitative MR Imaging for Patients Receiving Radiation Therapy for Liver Cancer
Montefiore Medical Center
NCT06899152
Study of Bevacizumab in Combination With Chemoimmunotherapy and Atezolizumab in Patients With Extensive Stage Small Cell Lung Cancer and Liver Metastases
Kamya Sankar
NCT05588388
Proton Therapy in the Treatment of Liver Metastases
Loma Linda University
NCT01697371
A Study of Single Fraction Stereotactic Body Radiation Therapy (SBRT) Guided by Magnetic Resonance Imaging (MRI) in People With Liver Metastasis From Colorectal Cancer
Memorial Sloan Kettering Cancer Center
NCT06130280
OAR-Based, Dose Escalated SBRT With Real Time Adaptive MRI Guidance for Liver Metastases
University of Wisconsin, Madison
NCT04020276
Platform Study of Immunotherapy Combinations in Colorectal Cancer Liver Metastases
Weill Medical College of Cornell University
NCT06300463
Promoting Immunotherapy Efficacy With Low-Dose Liver RT
Jordan Kharofa
NCT07225036
Hepzato Kit and Opdualag for Metastatic Melanoma and Liver Metastasis
University of Wisconsin, Madison
NCT07281924
Liver SBRT in Combination With Immune Checkpoint Inhibition in Patients With Metastatic Non-small Cell Lung Cancer
VA Ann Arbor Healthcare System
NCT05430009
Lesion Detection Assessment in the Liver: Standard vs Low Radiation Dose Using Varied Post-Processing Techniques
M.D. Anderson Cancer Center
NCT03151564
The HistoSonics System for Treatment of Primary and Metastatic Liver Tumors Using Histotripsy
HistoSonics
NCT04572633
Senior Adult Hepatobiliary Prehab Study
H. Lee Moffitt Cancer Center and Research Institute
NCT05921552
Hepatic Resection for Metastatic Pancreatic Cancer
Duke University
NCT02892305
Hepatic Artery Infusional Floxuridine to Treat Pancreatic Cancer Liver Metastases
Corewell Health West
NCT03856658
Copper Cu 64-DOTA-Trastuzumab PET in Predicting Response to Treatment With Ado-Trastuzumab Emtansine in Patients With Metastatic HER2 Positive Breast Cancer
City of Hope Medical Center
NCT02226276
Pilot Study to Assess Lung Shunting of Yttrium-90 Microspheres Using PET/CT
University of Cincinnati
NCT02119065
Comprehensive Electronic Cancer Support System for the Treatment of Cancer Related Symptoms
University of Pittsburgh
NCT01640522
Individualized Stereotactic Body Radiotherapy of Liver Metastases
Massachusetts General Hospital
NCT01239381
A Study Evaluating Safety, Pharmacokinetics, Pharmacodynamics, And Clinical Activity Of RO7119929 (TLR7 Agonist) In Participants With Unresectable Advanced Or Metastatic Hepatocellular Carcinoma, Biliary Tract Cancer, Or Solid Tumors With Hepatic Metastases
Hoffmann-La Roche
NCT04338685
Hepatic Arterial Infusion of Floxuridine, Gemcitabine Hydrochloride, and Radiolabeled Monoclonal Antibody Therapy in Treating Liver Metastases in Patients With Metastatic Colorectal Cancer Previously Treated With Surgery
City of Hope Medical Center
NCT00645710
CAR-T Hepatic Artery Infusions and Sir-Spheres for Liver Metastases
Roger Williams Medical Center
NCT02416466
CAR-T Hepatic Artery Infusions or Pancreatic Venous Infusions for CEA-Expressing Liver Metastases or Pancreas Cancer
Roger Williams Medical Center
NCT02850536
Hypofractionated Image Guided Radiation Therapy in Treating Patients With Stage IV Breast Cancer
University of Chicago
NCT01706432
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 6 |
| Phase 2 | 7 |
Top Sponsors
Named interventions
Most-linked intervention names on Liver Metastases records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Liver Metastases trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Liver Metastases page
28 registered trials, 14 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 14 Liver Metastases trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Roger Williams Medical Center sponsors the most Liver Metastases trials on record, review their full trial history before evaluating a specific study. See Roger Williams Medical Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Liver Metastases condition card totals 28 registered trials; most-linked intervention anti-CEA CAR-T cells; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.